Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Anti-TNF-alpha therapy for sight threatening uveitis.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM.

Br J Ophthalmol. 2005 May;89(5):533-6.

2.

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J.

Eye (Lond). 2005 Aug;19(8):841-5.

PMID:
15389273
3.

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.

Markomichelakis N, Delicha E, Masselos S, Sfikakis PP.

Am J Ophthalmol. 2012 Sep;154(3):534-541.e1. doi: 10.1016/j.ajo.2012.03.035. Epub 2012 Jul 11.

PMID:
22789563
4.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
5.

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.

Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. Epub 2007 Jun 7.

PMID:
17554481
6.

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.

Morris DS, Gavin MP, Sturrock RD.

Adv Exp Med Biol. 2003;528:557-9. No abstract available.

PMID:
12918763
7.

Infliximab in the treatment of refractory posterior uveitis.

Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ.

Ophthalmology. 2003 Jul;110(7):1449-53.

PMID:
12867408
8.

Adalimumab for sight-threatening uveitis in Behçet's disease.

Mushtaq B, Saeed T, Situnayake RD, Murray PI.

Eye (Lond). 2007 Jun;21(6):824-5. Epub 2006 Apr 7.

PMID:
16601736
9.

Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.

Tognon S, Graziani G, Marcolongo R.

Ann N Y Acad Sci. 2007 Sep;1110:474-84.

PMID:
17911463
10.

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.

Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R.

Int Ophthalmol. 2010 Oct;30(5):577-81. doi: 10.1007/s10792-010-9372-1. Epub 2010 May 20.

PMID:
20490893
11.
12.

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.

Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F.

Rheumatology (Oxford). 2007 Jul;46(7):1161-4. Epub 2007 May 3.

PMID:
17478466
13.

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stübiger N.

Br J Ophthalmol. 2003 Apr;87(4):423-31.

14.

Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients.

Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevin L.

Presse Med. 2005 Jul 23;34(13):916-8.

15.

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M.

Arthritis Res Ther. 2012 May 1;14(3):R99. doi: 10.1186/ar3824.

16.

Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.

Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S58-63. Epub 2011 Sep 27.

PMID:
21968238
17.

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.

Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M.

Ophthalmology. 2014 Oct;121(10):1877-84. doi: 10.1016/j.ophtha.2014.04.042. Epub 2014 Jun 18.

PMID:
24950593
18.

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN.

Lancet. 2001 Jul 28;358(9278):295-6.

PMID:
11498218
19.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625
20.

Supplemental Content

Support Center